Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S.

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed ...

Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2025, but sales fell by 5.6% year on ...

US generics major Viatris has won US Food and Drug Administration (FDA) approval for iron sucrose injection, USP, an ...

Investing.com -- Viatris Inc (NASDAQ: VTRS) stock rose 2.6% following the U.S. Food and Drug Administration’s approval of the company’s Iron Sucrose Injection, USP, the first generic version of ...

David Einhorn's Greenlight Capital took new positions in Fluor (FLR), with 760.6K shares, and Victoria's Secret (VSCO), with ...

Q2 2025 Earnings Call Transcript August 12, 2025 Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron ...

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 Pivotal Phase 3 CYPRESS study enrollment on track to complete ...